Related Experiment Video
Updated: Jan 18, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.7K
[INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS]
Nicola Fazaa1, Reut Shashar1, Kamil Malshy1
1Department of Urology, Rambam Health Care Campus.
Harefuah
|September 11, 2025
Summary
Bladder cancer treatment failure is common with Bacillus Calmette-Guerin (BCG). New therapies are being explored to reduce the need for bladder removal in patients with non-muscle invasive bladder cancer.
Area of Science:
- Oncology
- Urology
Background:
- Bladder cancer is classified as muscle-invasive or non-muscle-invasive.
- Non-muscle-invasive bladder cancer (NMIBC) is risk-stratified for recurrence and progression.
- High-risk NMIBC often fails conventional intravesical Bacillus Calmette-Guerin (BCG) therapy, leading to radical cystectomy.
Purpose of the Study:
- To review current and investigational treatments for NMIBC.
- To explore novel therapeutic options to prevent disease recurrence and progression.
- To reduce the need for radical cystectomy in NMIBC patients.
Main Methods:
- Review of current approved therapeutic options.
- Overview of innovative investigational treatments.
- Exploration of systemic and intravesical treatment modalities.
Main Results:
- Conventional BCG therapy has a significant failure rate (30-50%).
- Approved options include intravesical gemcitabine/docetaxel and pembrolizumab.
- Investigational treatments like TAR-200 and cretostimogene grenadenorepvec show promise.
Conclusions:
- Novel therapeutic strategies are crucial for managing high-risk NMIBC.
- Emerging treatments aim to improve outcomes and spare the bladder.
- Further research is needed to establish the efficacy of new NMIBC therapies.
